Publications and Guidelines

ETA/EUGOGO Guidelines

The 2021 European Group on Graves’ Orbitopathy (EUGOGO) Clinical Practice Guidelines for the Management of Graves’ Orbitopathy.

The 2016 European Thyroid Association/European Group on Graves’ Orbitopathy Guidelines for the Management of Graves’ Orbitopathy

Publications

Our multicentric network of Joint TECs around Europe published a huge number of papers in scientific journals. Papers on assessment and treatment recommendations, observational studies as well as RCTs –all of them reflecting the scientific power of a multidisciplinary approach.

Presentation of Graves’ orbitopathy within European Group On Graves’ Orbitopathy (EUGOGO) centres from 2012 to 2019 (PREGO III)

Br J Ophthalmology. 2023;epub ahead of print: doi:10.1136/bjo-2022-322442 A Schuh, A Goksun, L Baldeschi, CR Hintschich et al. on behalf of EUGOGO.

The 2021 European Group on Graves’ orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves’ orbitopathy.

European Journal of Endocrinology. 2021;185(4):G43-G67. doi.org/10.1530/EJE-21-0479 L Bartalena, GJ Kahaly, L Baldeschi, CM Dayan, A Eckstein, C Marcocci, M Marinò, B Vaidya andWM Wiersinga on behalf of EUGOGO.

Asymmetry indicates worse disease in Graves’ Orbitopathy: results from a prospective cross-sectional multicentre study.

J Endocrinol Invest. 2020 Dec;43(12):1717-1722 P Perros, M Zarkovic et al. on behalf of the European Group on Graves’ Orbitopathy (EUGOGO).

Predictive score for the development or progression of Graves’ orbitopathy in patients with newly diagnosed Graves’ hyperthyroidism.

Eur J Endocrinol. 2018 Jun;178(6):635-643. doi: 10.1530/EJE-18-0039. Epub 2018 Apr 12. PMID: 29650691 W. Wiersinga, M. Zarkovic, L. Bartalena, S. Donati, P. Perros, O. Okosieme, D. Morris, N. Fichter, J. Lareida, G. von Arx, C. Daumerie, M. Buralcu, G. Kahaly, S. Pitz, B. Beleslin, J. Ciric, G. Ayvaz, O. Konuk, F. Törüner, M. Salvi, D. Covelli, N. Curro, L. Hegedüs, T. Brix on behalf of EUGOGO.

Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves’ orbitopathy (MINGO): a randomised, observer-masked, multicentre trial.

Lancet Diabetes Endocrinol. 2018 Apr;6(4):287-298. doi: 10.1016/S2213-8587(18)30020-2. Epub 2018 Jan 31. PubMed PMID: 29396246. Kahaly GJ, Riedl M, König J, Pitz S, Ponto K, Diana T, Kampmann E, Kolbe E, Eckstein A, Moeller LC, Führer D, Salvi M, Curro N, Campi I, Covelli D, Leo M, Marinò M, Menconi F, Marcocci C, Bartalena L, Perros P, Wiersinga WM; European Group on Graves’ Orbitopathy (EUGOGO).

Does early response to intravenous glucocorticoids predict the final outcome in patients with moderate-to-severe and active Graves’ orbitopathy?

J Endocrinol Invest. 2017 May;40(5):547-553. doi: 10.1007/s40618-017-0608-z. Epub 2017 Feb 7. PubMed PMID: 28176220. Bartalena L, Veronesi G, Krassas GE, Wiersinga WM, Marcocci C, Marinò M, Salvi M, Daumerie C, Bournaud C, Stahl M, Sassi L, Azzolini C, Boboridis KG, Mourits MP, Soeters MR, Baldeschi L, Nardi M, Currò N, Boschi A, Bernard M, von Arx G, Perros P, Kahaly GJ; European Group on Graves’ Orbitopathy (EUGOGO).